MENU
+Compare
XXII
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$3.07
Change
+$0.12 (+4.07%)
Capitalization
1.06M

XXII 22nd Century Group Inc Forecast, Technical & Fundamental Analysis

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis... Show more

Industry: #Miscellaneous
XXII
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XXII with price predictions
Jul 25, 2025

XXII's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for XXII turned positive on July 07, 2025. Looking at past instances where XXII's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XXII advanced for three days, in of 223 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XXII declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XXII entered a downward trend on July 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.291) is normal, around the industry mean (4.147). XXII has a moderately low P/E Ratio (0.003) as compared to the industry average of (20.308). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.987). XXII has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.053). P/S Ratio (0.022) is also within normal values, averaging (2.132).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.

View a ticker or compare two or three
XXII
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

XXII is expected to report earnings to fall 96.25% to -7 cents per share on August 08

22nd Century Group Inc XXII Stock Earnings Reports
Q2'23
Est.
$-0.07
Q1'25
Missed
by $1.02
Q4'24
Missed
by $16.80
Q1'23
Missed
by $0.01
Q4'22
Missed
by $0.06
The last earnings report on May 13 showed earnings per share of -188 cents, missing the estimate of -87 cents. With 224.66K shares outstanding, the current market capitalization sits at 1.06M.
A.I. Advisor
published General Information

General Information

a plant biotechnology company

Industry Tobacco

Profile
Fundamentals
Details
Industry
Miscellaneous
Address
321 Farmington Road
Phone
+1 716 270-1523
Employees
64
Web
https://www.xxiicentury.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SMR51.670.64
+1.25%
NuScale Power Corp
NETDU11.31N/A
N/A
Nabors Energy Transition Corp
VTLE18.58-0.15
-0.80%
Vital Energy
BSAC23.42-0.27
-1.14%
Banco Santander-Chile
BNR6.80-1.57
-18.76%
Burning Rock Biotech Limited

XXII and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, XXII has been loosely correlated with SMORF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if XXII jumps, then SMORF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XXII
1D Price
Change %
XXII100%
-3.28%
SMORF - XXII
42%
Loosely correlated
N/A
RLX - XXII
12%
Poorly correlated
-0.44%
BTAFF - XXII
11%
Poorly correlated
+1.76%
TPB - XXII
11%
Poorly correlated
-2.16%
UVV - XXII
7%
Poorly correlated
-1.67%
More